Rhythm Biosciences Secures Manufacturing Agreement With US-Based Manufacturer for Cancer Blood Test Product

MT Newswires Live

Feb 03

Rhythm Biosciences (ASX:RHY) has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.

The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.

The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608479418"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608479418\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608479418?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 15:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608479418","market":"hk","top_or_hot":-1,"title":"Rhythm Biosciences Secures Manufacturing Agreement With US-Based Manufacturer for Cancer Blood Test Product","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RHYN.AU\">Rhythm Biosciences</a> (ASX:RHY) has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.</p><p>The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.</p><p>The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rhythm Biosciences Secures Manufacturing Agreement With US-Based Manufacturer for Cancer Blood Test Product</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRhythm Biosciences Secures Manufacturing Agreement With US-Based Manufacturer for Cancer Blood Test Product\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-03 15:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RHYN.AU\">Rhythm Biosciences</a> (ASX:RHY) has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.</p><p>The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.</p><p>The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7124","symbol_name":"保健护理服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2608479418","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608479418","pubTimestamp":1770102389,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Rhythm Biosciences  has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7124":"保健护理服务","RHY.AU":"RHYTHM BIOSCIENCES LTD"},"translate_title":"Rhythm Biosciences与美国制造商签订癌症血液检测产品制造协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHY.AU":1},"content_text":"Rhythm Biosciences (ASX:RHY) has executed a multi-year commercial supply agreement with Quansys Biosciences, a US-based manufacturer, to produce ColoSTAT reagent kits, the company's blood test product for cancer, according to a Tuesday Australian bourse filing.The company said that the agreement provides scalable manufacturing capacity to support the ColoSTAT Access Program and commercial rollout and includes provisions for minimum order volumes and a pricing framework to support anticipated operational requirements.The company added that the supply partnership reduces manufacturing scale-up and quality system risk following two years of successful assay development collaboration.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}